{
    "nct_id": "NCT03431350",
    "official_title": "A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer",
    "inclusion_criteria": "Healthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)\n* Active malignancies (that is, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. The only allowed exceptions are: non-muscle invasive bladder cancer; skin cancer (non-melanoma or melanoma); breast cancer; malignancy that is considered cured with minimal risk of recurrence\n* Active infection requiring systemic therapy\n* Allergies, hypersensitivity, or intolerance to niraparib or the corresponding excipients\n\nCombination 3:\n\n* Symptomatic brain metastases\n* Prior disease progression during combination treatment with AA and poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitor (PARPi). Prior discontinuation of treatment with AA or PARPi due to AA- or PARPi-related toxicity",
    "miscellaneous_criteria": "Inclusion Criteria for Combination 3:\n\n* Diagnosed with mCRPC, who in the opinion of the investigator may benefit from treatment in Combination 3 of this study\n* Able to continue gonadotropin releasing hormone analogue (GnRHa) therapy during the study if not surgically castrate (that is, subjects who has not undergone bilateral orchiectomy).\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of less than or equal to (<=) 1\n* Toxicity associated with prior chemotherapy or radiotherapy has resolved to Grade <= 1 (except alopecia or Grade <= 2 neuropathy) at screening\n* Participant must agree not to donate sperm while on study treatment, and for 3 months following the last dose of study treatment"
}